Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib + donafenib + tislelizumab for unresectable hepatocellular carcinoma (single-arm, first-line)
ChiCTR2600128148Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of jaktinib, donafenib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
jaktinibdonafenibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600128148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128148.